AU2002313758B2 - Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure - Google Patents

Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure Download PDF

Info

Publication number
AU2002313758B2
AU2002313758B2 AU2002313758A AU2002313758A AU2002313758B2 AU 2002313758 B2 AU2002313758 B2 AU 2002313758B2 AU 2002313758 A AU2002313758 A AU 2002313758A AU 2002313758 A AU2002313758 A AU 2002313758A AU 2002313758 B2 AU2002313758 B2 AU 2002313758B2
Authority
AU
Australia
Prior art keywords
disease
donor
blood pressure
patient
pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002313758A
Other languages
English (en)
Other versions
AU2002313758A1 (en
Inventor
Mark W. Dewhirst
Claude A. Piantadosi
Jonathan S. Stamler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of AU2002313758A1 publication Critical patent/AU2002313758A1/en
Application granted granted Critical
Publication of AU2002313758B2 publication Critical patent/AU2002313758B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002313758A 2001-11-13 2002-08-26 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure Ceased AU2002313758B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/986,807 US6472390B1 (en) 2001-11-13 2001-11-13 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
US09/986,807 2001-11-13
PCT/US2002/025937 WO2003041713A1 (en) 2001-11-13 2002-08-26 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure

Publications (2)

Publication Number Publication Date
AU2002313758A1 AU2002313758A1 (en) 2003-07-24
AU2002313758B2 true AU2002313758B2 (en) 2006-06-22

Family

ID=25532762

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002313758A Ceased AU2002313758B2 (en) 2001-11-13 2002-08-26 Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure

Country Status (6)

Country Link
US (1) US6472390B1 (enExample)
EP (1) EP1458397A4 (enExample)
JP (2) JP5259038B2 (enExample)
AU (1) AU2002313758B2 (enExample)
CA (1) CA2467159C (enExample)
WO (1) WO2003041713A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003287006B2 (en) * 2002-10-25 2010-03-18 Duke University Preventing desensitization of receptors

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
US7516742B2 (en) 1999-11-24 2009-04-14 Cardinal Health 207, Inc. Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing
US6432077B1 (en) 2000-12-26 2002-08-13 Sensormedics Corporation Device and method for treatment of surface infections with nitric oxide
US7122018B2 (en) 2000-12-26 2006-10-17 Sensormedics Corporation Device and method for treatment of wounds with nitric oxide
US20040225275A1 (en) * 2001-08-02 2004-11-11 Reynolds James Dixon Fetal physiology during maternal surgery or diagnosis
US6676855B2 (en) * 2001-08-02 2004-01-13 Duke University Use of a blood-flow decrease preventing agent in conjunction with insufflating gas
GB0125222D0 (en) * 2001-10-19 2001-12-12 Barts & London Nhs Trust Composition for the treatment of microbial infections
US20040110691A1 (en) * 2001-11-13 2004-06-10 Stamler Jonathan S. Thiol reactive agents as a therapeutic modality
JP2005527834A (ja) * 2002-05-29 2005-09-15 デューク・ユニバーシティー 血液ガス中の一酸化窒素の測定およびそれに基づく処置
US7531133B2 (en) 2002-09-10 2009-05-12 Pulmonox Technologies Corporation Use of nitric oxide gas in an extracorporeal circuitry to treat blood plasma
JP5564157B2 (ja) * 2003-07-09 2014-07-30 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ 心臓血管状態の処置のための亜硝酸塩の使用方法
JP2007509163A (ja) * 2003-10-22 2007-04-12 フレッド ハッチンソン キャンサー リサーチ センター 組織および臓器においてスタシスを誘導する方法、組成物、および装置
US20070270350A1 (en) * 2003-12-23 2007-11-22 Musc Foundation For Research Development Methods and Compositions for the Prevention and Treatment of Inflammatory Diseases or Conditions
US20050182136A1 (en) * 2004-02-17 2005-08-18 Allen Jeremais N-acetylcysteine compositions and methods for the treatment and prevention of endothelial dysfunction
WO2005107384A2 (en) * 2004-03-31 2005-11-17 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
FR2868314B1 (fr) * 2004-04-05 2008-10-24 Therabel Pharmaceuticals Ltd Nouvelle utilisation therapeutique de la molsidomine et de ses sels pharmaceutiquement acceptables
US8518457B2 (en) 2004-05-11 2013-08-27 Pulmonox Technologies Corporation Use of inhaled gaseous nitric oxide as a mucolytic agent or expectorant
CN1950120B (zh) 2004-05-11 2010-10-20 伟亚医疗森迪斯公司 一氧化氮气体的间歇计量
US7362274B1 (en) * 2004-07-09 2008-04-22 Huan-Cheng Lien Coupled feed-in butterfly shaped left/right hand circularly polarized microstrip antenna
WO2006125123A2 (en) * 2005-05-19 2006-11-23 University Of Cincinnati Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite
AU2006249323B2 (en) 2005-05-27 2012-08-30 The University Of North Carolina At Chapel Hill Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
CA2634473A1 (en) * 2006-02-17 2007-08-30 Nitromed, Inc. Methods using hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
WO2007103534A2 (en) * 2006-03-07 2007-09-13 Nitrox, Llc Ethyl nitrite as a gastrointestinal smooth muscle relaxant and diagnostic and therapeutic uses thereof
WO2007146311A2 (en) * 2006-06-12 2007-12-21 N30 Pharmaceuticals, Llc Compositions and methods for protecting newborn lung development with ethyl nitrite
US8079998B2 (en) 2006-10-20 2011-12-20 Pulmonox Technologies Corporation Methods and devices for the delivery of therapeutic gases including nitric oxide
WO2009035550A1 (en) * 2007-09-10 2009-03-19 Duke University Treating patients with subarachnoid hemorrhage
US20090196930A1 (en) * 2007-12-27 2009-08-06 Aires Pharmaceuticals, Inc. Aerosolized nitrite and nitric oxide -donating compounds and uses thereof
AU2009244790B2 (en) * 2008-05-09 2013-09-12 Duke University Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells
CA3062005C (en) 2009-08-21 2022-02-15 Novan, Inc. Topical gels comprising nitric oxide-releasing polysiloxane macromolecules and uses thereof
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012118829A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same
JP6251849B2 (ja) * 2015-10-13 2017-12-20 学校法人慶應義塾 椎間板変性症、腰痛改善を処置するための医薬組成物、及び治療薬のスクリーニング方法
WO2019073045A1 (en) 2017-10-12 2019-04-18 Bdd Berolina Drug Development Gmbh USE OF DONORS OF NO

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4900719A (en) * 1988-08-05 1990-02-13 The Ohio State University Nitrosothiols as hypotensive agents
US5208233A (en) * 1989-09-15 1993-05-04 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
DE122007000103I1 (de) * 1990-12-05 2008-04-03 Gen Hospital Corp Verwendung von NO zur Behandlung der persistenten pulmonalen Hypertonie des Neugeborenen
CA2129630C (en) * 1992-02-07 2003-09-23 Anthony E. Bolton Method of increasing the concentration of nitric oxide in blood
US5385940A (en) * 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
US5861168A (en) * 1993-06-11 1999-01-19 The Board Of Trustees Of The Leland Stanford Junior University Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US5869539A (en) * 1996-04-17 1999-02-09 Board Of Regents, The University Of Texas System Emulsions of perfluoro compounds as solvents for nitric oxide (NO)
PT951292E (pt) * 1996-09-27 2007-06-18 Univ Columbia Métodos de tratamento de uma perturbação isquémica e de melhoria das consequências de acidente vascular cerebral.
FR2757864B1 (fr) * 1996-12-30 1999-03-19 Centre Nat Rech Scient Anticorps reconnaissant specifiquement une proteine nitrosylee, leur procede de preparation, leur utilisation therapeutique et diagnostique
EP1037621A4 (en) * 1997-10-15 2004-01-21 Univ Jefferson NITROGEN OXYD DONOR COMPOSITIONS, METHODS, APPARATUS, AND KITS FOR PREVENTING OR REDUCING VASCARSIONS OR VASCULAR SPAS IN A MAMMAL
JPH11217330A (ja) * 1998-01-30 1999-08-10 Sumitomo Pharmaceut Co Ltd 神経栄養因子分泌促進剤
US6265420B1 (en) * 1998-06-23 2001-07-24 Medinox, Inc. Use of nitric oxide scavengers to treat side effects caused by therapeutic administration of sources of nitric oxide
US6007824A (en) * 1998-07-09 1999-12-28 Duckett; Melvin J. Natural composition and method for the treatment of sexual dysfunction
US6314956B1 (en) * 1999-09-08 2001-11-13 Duke University Pulmonary delivery of NO group-containing compound in gas form to treat respiratory, cardiac and blood disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
References cited in WO 03/041713 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003287006B2 (en) * 2002-10-25 2010-03-18 Duke University Preventing desensitization of receptors

Also Published As

Publication number Publication date
EP1458397A4 (en) 2007-03-07
JP5259038B2 (ja) 2013-08-07
JP2005509004A (ja) 2005-04-07
WO2003041713A1 (en) 2003-05-22
JP2009167223A (ja) 2009-07-30
US6472390B1 (en) 2002-10-29
CA2467159A1 (en) 2003-05-22
CA2467159C (en) 2012-03-13
EP1458397A1 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
CA2467159C (en) Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
AU2002313758A1 (en) Use of therapeutic dosages for nitric oxide donors which do not significantly lower blood pressure or pulmonary artery pressure
Fang et al. The role of NO in COVID-19 and potential therapeutic strategies
Cooke NO and angiogenesis
JP5004391B2 (ja) Ｎｏ基化合物で心肺疾病を処置する方法
Cepinskas et al. Inflammatory response in microvascular endothelium in sepsis: role of oxidants
JP5564158B2 (ja) 亜硝酸塩によって特定の心臓血管状態を処置する方法
Troncy et al. Extra-pulmonary effects of inhaled nitric oxide in swine with and without phenylephrine
Lange et al. Role of nitric oxide in shock: the large animal perspective
JP2010159307A (ja) レセプターの脱感作の予防
Minami et al. Contribution of vascular nitric oxide to basal blood pressure in conscious spontaneously hypertensive rats and normotensive Wistar Kyoto rats
Hirota Hypoxia-dependent signaling in perioperative and critical care medicine
Abolfazli et al. Regulatory effects of resveratrol on nitric oxide signaling in cardiovascular diseases
Lin et al. Sodium octanoate alleviates cardiac and cerebral injury after traumatic cardiac arrest in a porcine model
JP2020525511A (ja) 低濃度のキセノンおよびアルゴンを含有するガス混合物は血栓溶解剤の触媒活性を阻害することなく神経保護を提供する
Lee et al. Effect of high-dose vitamin C on oxygen free radical production and myocardial enzyme after tourniquet ischaemia–reperfusion injury during bilateral total knee replacement
Hong et al. Perioperative assessment of terlipressin infusion during living donor liver transplantation
US8974836B2 (en) Angiogenesis regulating composition and method for regulating angiogenesis
Jiang et al. SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization
Cheung et al. Inhaled nitric oxide inhibits the release of matrix metalloproteinase-2, but not platelet activation, during extracorporeal membrane oxygenation in adult rabbits
RU2409373C2 (ru) Применение солей лития для лечения острой почечной недостаточности
Ward et al. Regulation of baseline vascular resistance in the canine diaphragm by nitric oxide
RU2789253C1 (ru) Способ реабилитации пациентов, перенесших COVID-19
GB2600668A (en) Alpha Lipoic Acid (A-ALA) and Alpha Lipoic Acid (R-ALA) As a Pharmaceutical Product for Intravenous Application to reduce Inflammation from infection.
RU2807236C1 (ru) Способ коррекции метаболического ацидоза в остром периоде ожоговой болезни

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired